TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded TriSalus Life Sciences to “Sell” from “Hold.” The broader analyst consensus remains “Hold,” with an average price target of $7.50, while ratings include two Buys, one Hold, and one Sell.
• TriSalus shares opened at $5.27 after a reported 6.4% decline, with a market capitalization of approximately $323.7 million. The stock has traded between $2.20 and $7.95 over the past year.
• The company’s latest quarterly results matched expectations with an adjusted loss of $0.16 per share, while revenue of $11.41 million exceeded the $10.27 million analyst estimate.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

Several other equities analysts have also issued reports on the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Lake Street Capital dropped their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $7.50.

TriSalus Life Sciences Stock Down 6.4%

Shares of NASDAQ:TLSI opened at $5.27 on Friday. The stock has a market cap of $323.68 million, a price-to-earnings ratio of -4.05 and a beta of 0.43. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. TriSalus Life Sciences has a 12-month low of $2.20 and a 12-month high of $7.95. The business's 50 day moving average is $4.39 and its 200 day moving average is $4.31.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, meeting analysts' consensus estimates of ($0.16). The company had revenue of $11.41 million during the quarter, compared to analysts' expectations of $10.27 million.

Institutional Trading of TriSalus Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Cura Wealth Advisors LLC purchased a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at $36,000. JPMorgan Chase & Co. grew its position in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock worth $41,000 after acquiring an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in TriSalus Life Sciences in the second quarter worth $47,000. Invesco Ltd. bought a new position in TriSalus Life Sciences in the fourth quarter valued at $72,000. Finally, Abel Hall LLC bought a new position in TriSalus Life Sciences in the fourth quarter valued at $73,000. Hedge funds and other institutional investors own 2.58% of the company's stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source